When it was named in a patent-infringement suit filed by Benitec, Nucleonics declined to go the way of its co-defendants and settle the matter with a license to Benitec’s DNA-directed RNAi technology.

Instead, Nucleonics decided to fight and began launching attacks of its own. Now it appears that the company’s strategy is about to start paying off: Following a review of two Benitec patents made at the behest of Nucleonics, the Australian patent office (known as IP Australia) is poised to begin proceedings that could result in the revocation of the patents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.